Newscast – Page 123 – media

NHS to support 138 entrepreneurs on new medical technologies

The National Health Service (NHS) in the UK is set to support 138 entrepreneurs among its staff, through its clinical entrepreneurs’ programme, in the design and development of new healthcare technologies and innovations.
- Source: medicaldevice-network
- 633
- January 15, 2018
healthcare technologies and innovations NHS polices
New IVF technique hailed as the ‘most exciting advance in fertility treatment for 40 years’

A new IVF method that takes thousands of pictures of embryos to select the best eggs has increased the likelihood of a baby being born by 25 percent.
- Source: Daily Mail
- 524
- January 15, 2018
IVF pregnancy Researches
New AI system for lung cancer and heart disease

Artificial intelligence is gradually being adopted by health services to assist medics with the diagnosis of serious diseases. In one new development, scientists in Oxford, U.K. have launched an AI system for heart disease.
- Source: Digital Journal
- 976
- January 15, 2018
AI heart attacks lung cancer Researches
NHS Confed orders reports into NHS funding needs

The NHS Confederation has tasked the Institute for Fiscal Studies and the Health Foundation with analysing the funding needs of the UK’s health and care systems over the next 15 years.
- Source: pharmatimes
- 526
- January 12, 2018
health NHS polices
Depression medication initiation may lower oral antidiabetic drug adherence in diabetes

Adults with type 2 diabetes and major depressive disorders who begin using second-generation antipsychotics are more likely to have at least a 10% decline in oral antidiabetic drug use 180 to 365 days after initiation compared with nonusers of second-generation antipsychotics, according to a study.
- Source: Healio
- 647
- January 12, 2018
antipsychotics diabetes Researches
Sex hormone-binding globulin associated with androgen deficiency

Higher levels of sex hormone-binding globulin were associated with androgen deficiency in men, independent of total testosterone level, researchers in Italy reported.
- Source: healio
- 442
- January 12, 2018
androgen deficiency Researches sex hormone
Celgene to Acquire Impact Biomedicines, Adding Fedratinib to Its Pipeline of Novel Therapies for Hematologic Malignancies

Celgene Corporation (CELG) and Impact Biomedicines today announced the signing of a definitive agreement in which Celgene will acquire Impact Biomedicines, which is developing fedratinib for myelofibrosis and polycythemia vera. Under the terms of the agreement, Celgene will pay approximately $1.1 billion upfront and up to $1.25 billion in contingent payments based on regulatory approval milestones for myelofibrosis. Additional future payments for regulatory approvals in additional indications and sales-based milestones are also possible.
- Source: finance.yahoo
- 527
- January 12, 2018
Celgene FDA Fedratinib Impact Market Views myelofibrosis
GE Healthcare and Roche join forces to create clinical decision support tools

GE Healthcare and Roche have launched a partnership to assist clinicians in making better choices and help patients get individualized care.
- Source: MedCityNews
- 600
- January 12, 2018
Clinical Company Insight Roche
New AI technology significantly improves human kidney analysis

The ability to quantify the extent of kidney damage and predict the life remaining in the kidney, using an image obtained at the time when a patient visits the hospital for a kidney biopsy, now is possible using a computer model based on artificial intelligence (AI).
- Source: Medical Xpress
- 654
- January 12, 2018
AI kidney Researches
Novartis advances head-to-head superiority trials of Cosentyx® versus Humira®* and proposed biosimilar adalimumab**

Novartis announced the initiation of SURPASS, a head-to-head clinical trial of Cosentyx® (secukinumab) versus proposed biosimilar adalimumab** in ankylosing spondylitis (AS). SURPASS is the first head-to-head clinical trial in AS investigating superiority of Cosentyx in slowing spinal bone damage versus proposed biosimilar adalimumab**. SURPASS is currently recruiting patients, with the 'first patient first visit' already achieved in November 2017.
- Source: drugdu
- 744
- January 11, 2018
adalimumab** Company Insight Cosentyx® Novartis Researches

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.